[go: up one dir, main page]

MX2018004351A - Uso de medicamentos con propiedades neuroprotectoras para prevenir o reducir el riesgo del daño por isquemia-reperfusion en un sujeto. - Google Patents

Uso de medicamentos con propiedades neuroprotectoras para prevenir o reducir el riesgo del daño por isquemia-reperfusion en un sujeto.

Info

Publication number
MX2018004351A
MX2018004351A MX2018004351A MX2018004351A MX2018004351A MX 2018004351 A MX2018004351 A MX 2018004351A MX 2018004351 A MX2018004351 A MX 2018004351A MX 2018004351 A MX2018004351 A MX 2018004351A MX 2018004351 A MX2018004351 A MX 2018004351A
Authority
MX
Mexico
Prior art keywords
ischemia
subject
medications
risk
prevent
Prior art date
Application number
MX2018004351A
Other languages
English (en)
Other versions
MX391926B (es
Inventor
Vrabec Tamara
Original Assignee
Vrabec Tamara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vrabec Tamara filed Critical Vrabec Tamara
Publication of MX2018004351A publication Critical patent/MX2018004351A/es
Publication of MX391926B publication Critical patent/MX391926B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proveen métodos de tratamiento y prevención del daño por isquemia-reperfusión e el daño relacionado con hipoxia intermitente crónica mediante la administración de un compuesto neuroprotector; al sujeto que se beneficiaría del método de la invención se le puede prescribir o someter a un tratamiento anti-VEGF, por ejemplo, un régimen de tratamiento IVAV, o puede tener un diagnóstico de un trastorno como apnea del sueño.
MX2018004351A 2015-10-09 2016-10-11 Uso de medicamentos con propiedades neuroprotectoras para prevenir o reducir el riesgo del daño por isquemia-reperfusion en un sujeto. MX391926B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562239639P 2015-10-09 2015-10-09
US15/193,625 US10105371B2 (en) 2015-10-09 2016-06-27 Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
PCT/US2016/056341 WO2017062974A1 (en) 2015-10-09 2016-10-11 Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject

Publications (2)

Publication Number Publication Date
MX2018004351A true MX2018004351A (es) 2019-01-10
MX391926B MX391926B (es) 2025-03-21

Family

ID=58488718

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004351A MX391926B (es) 2015-10-09 2016-10-11 Uso de medicamentos con propiedades neuroprotectoras para prevenir o reducir el riesgo del daño por isquemia-reperfusion en un sujeto.
MX2022004837A MX2022004837A (es) 2015-10-09 2018-04-09 Uso de medicamentos con propiedades neuroprotectoras para prevenir o reducir el riesgo del da?o por isquemia-reperfusion en un sujeto.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022004837A MX2022004837A (es) 2015-10-09 2018-04-09 Uso de medicamentos con propiedades neuroprotectoras para prevenir o reducir el riesgo del da?o por isquemia-reperfusion en un sujeto.

Country Status (8)

Country Link
US (3) US10105371B2 (es)
EP (1) EP3359257B1 (es)
JP (3) JP7071269B2 (es)
CN (2) CN108601950A (es)
BR (1) BR112018007139A2 (es)
CA (1) CA3001464A1 (es)
MX (2) MX391926B (es)
WO (1) WO2017062974A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
CN110974828B (zh) * 2019-12-24 2023-03-31 苏州大学 化合物Axitinib在制备治疗脑血管疾病的药物中的应用及其药物组合物
CN113134116B (zh) * 2020-01-20 2022-09-06 山东威高宏瑞医学科技有限公司 内镜微创手术用的填充组合物及填充制剂
CN115066232B (zh) 2020-02-06 2024-12-10 视尔普斯眼科公司 用于治疗眼病的组合物和方法
CA3177005A1 (en) 2020-04-27 2021-11-04 Michael Goldstein Methods of treating allergic conjunctivitis
KR102485499B1 (ko) * 2022-07-15 2023-01-09 오가노이드사이언스 주식회사 신장 질환의 치료 또는 예방용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100854207B1 (ko) * 2007-04-04 2008-08-26 성공제 아그마틴의 망막 신경절 세포 보호 용도
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
KR20180021741A (ko) * 2015-05-29 2018-03-05 에쥐 세라피틱스, 인코포레이티드 시각 손실을 감소시키기 위한 조성물 및 방법
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject

Also Published As

Publication number Publication date
MX2022004837A (es) 2022-05-16
US10105371B2 (en) 2018-10-23
US20210299142A1 (en) 2021-09-30
JP2024103501A (ja) 2024-08-01
US12083128B2 (en) 2024-09-10
EP3359257B1 (en) 2025-05-28
JP2022107631A (ja) 2022-07-22
CN116211871A (zh) 2023-06-06
CA3001464A1 (en) 2017-04-13
US20190038636A1 (en) 2019-02-07
EP3359257A1 (en) 2018-08-15
JP2018530616A (ja) 2018-10-18
WO2017062974A1 (en) 2017-04-13
US11033557B2 (en) 2021-06-15
MX391926B (es) 2025-03-21
CN108601950A (zh) 2018-09-28
BR112018007139A2 (pt) 2018-11-06
JP7071269B2 (ja) 2022-05-18
US20170100410A1 (en) 2017-04-13
EP3359257A4 (en) 2019-06-19

Similar Documents

Publication Publication Date Title
MX2018004351A (es) Uso de medicamentos con propiedades neuroprotectoras para prevenir o reducir el riesgo del daño por isquemia-reperfusion en un sujeto.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2016015997A (es) Preparacion y uso de beta-d-nicotinamida ribosido cristalina.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2016010854A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r.
PH12017500153B1 (en) Compositions and methods of use for treating metabolic disorders
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
NI201500150A (es) TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método
EA201591758A1 (ru) Подкожное введение adamts13
PH12017501290A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
MX2022006770A (es) Dispersiones solidas de bendamustina e infusion continua.
CY1121566T1 (el) Νευροπροστατευτικο και ενδειξη αυτου
MX2016011881A (es) Medicamento de peptido en polvo seco.
BR112016016932A2 (pt) Tratamento de neoplasia
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
AR100734A1 (es) Método para tratar leucemia linfocítica crónica (cll)
BR112016012248A2 (pt) método de tratamento de nefropatia
IL250708A0 (en) Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers
NZ725067A (en) Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.
MX2016006882A (es) Nutricion infantil para el mejoramiento en la sensibilidad a la insulina mas adelante en la vida.
MX384453B (es) Métodos in vitro para identificar lactantes prematuros en riesgo de displasia broncopulmonar.
AR098670A1 (es) Inhibidor de sglt1
NZ725303A (en) Anti-tumor agent containing taxane compound, and anti-tumor effect enhancer